Robert J Mentz1,2, Marco Metra3, Gad Cotter4, Olga Milo4, Colleen McKendry2, Karen Chiswell2, Beth A Davison4, John G F Cleland5, Daniel M Bloomfield6, Howard C Dittrich7, Mona Fiuzat1,2, Piotr Ponikowski8, Michael M Givertz9, Adriaan A Voors10, John R Teerlink11, Christopher M O'Connor1,2. 1. Duke University Hospital, Medicine, Division of Cardiology, 2301 Erwin Road, Durham, NC 27713, USA. 2. Duke Clinical Research Institute, Durham, NC, USA. 3. University of Brescia, Brescia, Italy. 4. Momentum Research, Durham, NC, USA. 5. National Heart and Lung Institute, Imperial College London (Royal Brompton & Harefield Hospitals) and Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-upon-Hull, UK. 6. Merck Research Laboratories, Rahway, NJ, USA. 7. University of Iowa Carver College of Medicine Cardiovascular Research Center, Iowa City, IA, USA. 8. Medical University, Military Hospital, Wroclaw, Poland. 9. Brigham and Women's Hospital, Boston, MA, USA. 10. University of Groningen, Groningen, the Netherlands. 11. University of California at San Francisco (SF) and SF Veterans Affairs Medical Center, SF, CA, USA.
Abstract
BACKGROUND: Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown. METHODS AND RESULTS: In the PROTECT trial of 2033 AHF patients, we investigated the association between time of occurrence of WHF and intensity of therapy, with subsequent outcomes. WHF was defined by standardized, physician-determined assessment. Early WHF was defined as occurring on days 2-3 and late on days 4-7. Low intensity included restarting/increasing diuretics or vasodilators and high intensity included initiation of inotropes, vasopressors, inodilators, or mechanical support. Outcomes were death or cardiovascular/renal hospitalization over 60 days and death over 180 days. Of the 1879 patients with complete follow-up after day 7, 12.7% (n = 238) experienced WHF: 47.9% early and 52.1% late. Treatment intensity was low in 72.3% and high in 24.8% (2.9% missing). After adjusting for baseline predictors of outcome, WHF was associated with a trend toward increased 60-day death or cardiovascular/renal hospitalization [hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.99-1.60; P = 0.063] and increased 180-day death (HR 1.77; 95% CI 1.33-2.34; P < 0.001). There was no evidence of a differential association between the time of occurrence of WHF and outcomes. High-intensity therapy was not significantly associated with increased event rates (180-day mortality: HR 1.44; 95% CI 0.80-2.59 vs. low). CONCLUSIONS: Inhospital WHF was associated with increased 180-day death. The time of occurrence and intensity of WHF therapy may provide less prognostic information than whether or not WHF occurred.
BACKGROUND: Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown. METHODS AND RESULTS: In the PROTECT trial of 2033 AHF patients, we investigated the association between time of occurrence of WHF and intensity of therapy, with subsequent outcomes. WHF was defined by standardized, physician-determined assessment. Early WHF was defined as occurring on days 2-3 and late on days 4-7. Low intensity included restarting/increasing diuretics or vasodilators and high intensity included initiation of inotropes, vasopressors, inodilators, or mechanical support. Outcomes were death or cardiovascular/renal hospitalization over 60 days and death over 180 days. Of the 1879 patients with complete follow-up after day 7, 12.7% (n = 238) experienced WHF: 47.9% early and 52.1% late. Treatment intensity was low in 72.3% and high in 24.8% (2.9% missing). After adjusting for baseline predictors of outcome, WHF was associated with a trend toward increased 60-day death or cardiovascular/renal hospitalization [hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.99-1.60; P = 0.063] and increased 180-day death (HR 1.77; 95% CI 1.33-2.34; P < 0.001). There was no evidence of a differential association between the time of occurrence of WHF and outcomes. High-intensity therapy was not significantly associated with increased event rates (180-day mortality: HR 1.44; 95% CI 0.80-2.59 vs. low). CONCLUSIONS: Inhospital WHF was associated with increased 180-day death. The time of occurrence and intensity of WHF therapy may provide less prognostic information than whether or not WHF occurred.
Authors: Christopher M O'Connor; Robert J Mentz; Gad Cotter; Marco Metra; John G Cleland; Beth A Davison; Michael M Givertz; George A Mansoor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Mona Fiuzat; Daniel Wojdyla; Karen Chiswell; Barry M Massie Journal: Eur J Heart Fail Date: 2012-04-25 Impact factor: 15.534
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Margaret F Prescott; Christopher Edwards; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas Severin; John R Teerlink Journal: J Am Coll Cardiol Date: 2013-01-15 Impact factor: 24.094
Authors: Gad Cotter; Marco Metra; Beth A Davison; Stefanie Senger; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Olga Milo; Isaac Kobrin; Maurizio Rainisio; John J V McMurray; John R Teerlink Journal: Eur J Heart Fail Date: 2014-11-05 Impact factor: 15.534
Authors: Robert J Mentz; Gad Cotter; John G F Cleland; Susanna R Stevens; Karen Chiswell; Beth A Davison; John R Teerlink; Marco Metra; Adriaan A Voors; Liliana Grinfeld; Mikhail Ruda; Viacheslav Mareev; Chaim Lotan; Daniel M Bloomfield; Mona Fiuzat; Michael M Givertz; Piotr Ponikowski; Barry M Massie; Christopher M O'Connor Journal: Eur J Heart Fail Date: 2014-04-25 Impact factor: 15.534
Authors: John J V McMurray; John R Teerlink; Gadi Cotter; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Gad Cotter; Marco Metra; Beth Davison Weatherley; Howard C Dittrich; Barry M Massie; Piotr Ponikowski; Daniel M Bloomfield; Christopher M O'Connor Journal: Cardiology Date: 2009-10-20 Impact factor: 1.869
Authors: Beth Davison Weatherley; Olga Milo-Cotter; G Michael Felker; Nir Uriel; Edo Kaluski; Zvi Vered; Christopher M O'Connor; Kirkwood F Adams; Gad Cotter Journal: Fundam Clin Pharmacol Date: 2009-07-28 Impact factor: 2.748
Authors: Adam D DeVore; Bradley G Hammill; Puza P Sharma; Laura G Qualls; Robert J Mentz; Katherine Waltman Johnson; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez Journal: J Am Heart Assoc Date: 2014-07-11 Impact factor: 5.501
Authors: Marat Fudim; Christopher M O'Connor; Allison Dunning; Andrew P Ambrosy; Paul W Armstrong; Adrian Coles; Justin A Ezekowitz; Stephen J Greene; Marco Metra; Randall C Starling; Adriaan A Voors; Adrian F Hernandez; G Michael Felker; Robert J Mentz Journal: Eur J Heart Fail Date: 2017-10-29 Impact factor: 15.534
Authors: Lauren B Cooper; Bradley G Hammill; Puza P Sharma; Adam D DeVore; Robert J Mentz; Gregg C Fonarow; Peter S Pang; Lesley H Curtis; Adrian F Hernandez Journal: Am Heart J Date: 2015-09-11 Impact factor: 4.749
Authors: Jacob P Kelly; Lauren B Cooper; Dianne Gallup; Kevin J Anstrom; Horng H Chen; Margaret M Redfield; Christopher M O'Connor; Robert J Mentz; Adrian F Hernanadez; G Michael Felker Journal: Circ Heart Fail Date: 2016-08 Impact factor: 8.790
Authors: John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra Journal: Eur J Heart Fail Date: 2017-04-28 Impact factor: 15.534